Pathology & Oncology Research

, Volume 1, Issue 1, pp 54–59 | Cite as

Complement synthesis influencing factors produced by acute myeloid leukemia blast cells

  • Béla Schmidt
  • Márta Válay
  • Sarolta Nahajevszky
  • Ervin Pitlik
  • György Füst


In a previous study, we found hypercomplementaemia in the sera of acute myeloid leukemia patients. In this study we show that the supernatants of mononuclear cells, derived from peripheral blood taken in the blastic phase, from patients with acute myeloid leukemia (CM-AML) increased thein vitro complement protein synthesis of HepG2 hepatocellular carcinoma cells. This effect of CM-AML was mediated by heat labile soluble factors and involved the synthesis of mRNA and protein. Inhibition experiments with anti-cytokine antibodies and immunoaffinity chromatography revealed that this effect of CM-AML is mostly mediated by IL-1 and IL-6.

Key words

AML complement factor B Cl-INH C3 C4 IL-lb IL-2 IL-6 TNF 









tumor necrosis factor


complement factor 2


complement factor 3


complement factor 4


1-esterase inhibitor


acute myeloid leukemia


conditioned medium of mononuclear cells derived from the blood of a patient with AML


conditioned medium of peripheral blood mononuclear cells derived from the blood of a healthy volunteer


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lichtenfeld JL, Wernik PH, Mardiney MR and Zureo RM: Abnormalities of complement and its components in patients with acute leukemia. Hodgkin’s disease and sarcoma. Cancer Res 36: 3678–3685, 1976.PubMedGoogle Scholar
  2. 2.
    Nishioka K, Kawamura K, Hirdyamd T, Kawashima T, Shimada K and Kgure M: The complement system in tumor immunity: significance of elevated levels of complement in tumor bearing hosts. Ann NY Acad Sei 276: 303–315, 1976.CrossRefGoogle Scholar
  3. 3.
    Puday ÁT, Füst G and Csömör A: Serum complement levels in patients with cancer of the uterine cervix before and after radiation therapy. Neoplasma 27: 211–216, 1980.Google Scholar
  4. 4.
    Bach-Mortensen N, Osther K and Stroyer I: CL-esterase inactivators and C4 in malignant diseases. Lancet 2: 499–500, 1975.CrossRefGoogle Scholar
  5. 5.
    Verhdrgen H, De Cock W, De Cree J MD and Verbruggen F: Increase of serum complement levels in cancer patients with progressing tumors. Cancer 38: 1608–1613. 1976.CrossRefGoogle Scholar
  6. 6.
    Astrup J, Colstrup H and Frandsen B: Complement Cl -inactivator in the serum of patients with malignant disease. Acta Radiol Ther Phys Biol. 16. Fase 5: 394–400, 1977.Google Scholar
  7. 7.
    Do-Quang Minh, Czink E, Mód A, Füst G and Hollán SR: Serial complement measurements in patients with leukemia. Clin Lab Hematol 5: 23–24. 1983.Google Scholar
  8. 8.
    Gyapay G, Schmidt B, Válay M, Falus A, Anh-Tuan N, Pánya A, Kókai M, Ónody K, Mód A and Füst G: Effect of Conditioned Media of Acute Myeloid Blast Cells on Complement Synthesis by Cultured Human Cells of Monocyte and Hepatocyte Origin. Complement and Inflammation 8: 370–377, 1991.PubMedGoogle Scholar
  9. 9.
    Schmidt B, Gyapay G, Kramer J and Füst G: Complement Synthesis Regulating factors in the Conditioned Medium of Acute Myeloid Leukemia (AML) Blast Cells. Mol Immunol 30: (Suppl 1): 50, 1993.CrossRefGoogle Scholar
  10. 10.
    Alper CA, Johnson AM, Birtch AG and Moore FD: Human C3: evidence for the liver as the primary site of synthesis. Science 163: 286, 1969.PubMedCrossRefGoogle Scholar
  11. 11.
    Knowlrs BB, Howe CC and Aden DP: Human hepatocellular carcinoma cell lines secrete the major plasma proteins and Hepatitis surface antigen. Science 209: 497, 1983.CrossRefGoogle Scholar
  12. 12.
    Kurzrock R, Kantarijan H, Wetzler M, Estroy Z, Estey E, Troutman-Worden K, Guterman JU and Talpaz M: Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage. Exp Hematol 21: 80–85, 1993.PubMedGoogle Scholar
  13. 13.
    Griffun JD, Rambaldi A, Vellenga E, Young DC, Ostapovicz D and Cdnnistrd SA: Secretion of interleukin-l by acute myeloid leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood 70: 218–21, 1987.Google Scholar
  14. 14.
    Lopez M, Maroc N, Kerangueyen F, Bardin F, Coureoul M, Lavezzi C, Birg F and Mannani P: Coexpression of the genes for interleukin 6 and its receptor without apparent involvement in the proliferation of acute myeloid leukemia cells. Exp Hematol 19: 797–803, 1991.PubMedGoogle Scholar
  15. 15.
    Cimino G, Amadori S, Cava MC, De Sanctis V, Petti MC, Di Gregorio AO, Sgaduri C, Vgna L, Cimino G and Mandelli F: Serum Interleukin-2 (IL-2). soluble IL-2 receptors and tumor necrosis factor-alpha levels are significantly increased in acute myeloid leukemia patients. Leukemia 5: 32–35, 1991.PubMedGoogle Scholar
  16. 16.
    Falus A, Rokita H, Wale, E, Brozik M, Hidvëgi T and Merétey K: Hormonal regulation of complement biosynthesis in human cell lines - II. Upregulation of the biosynthesis of complement components C3, factor B. and C1 inhibitor by interleukin-6 and interleukin-1 in human hepatoma cell line. Mol Immunol 27: 197–201, 1990.PubMedCrossRefGoogle Scholar
  17. 17.
    Perlmutter DH, Dinarello CA, Punsal PI and Colten HR: Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression. J Clin Invest 78: 1349–1354, 1986.PubMedCrossRefGoogle Scholar
  18. 18.
    Wagteveld AJ, Esselink MT, Limburg P, Hulie MR and Vellenga E: The effects of IL-1- and IL-4 on the proliferation and secretion of growth factors by acute myeloblastic leukemic cells. Leukemia 6: 1020–1024, 1992.PubMedGoogle Scholar
  19. 19.
    Estrov Z, Kurzrock R, Estey E, Wetzler M, Ferrdjoli A, Harris D, Blake M, Gutterman JU and Talpaz M: Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. Blood 79: 1938–1945, 1992.PubMedGoogle Scholar
  20. 20.
    Rambaldi A, Torcia M, Dinarello CA, Barbui T and Cozzoloni F: Modulation of cell proliferation and cytokine production in AML by recombinant interleukin-1 receptor antagonist. Leukemia (Suppl 2): S10–12, 1993.Google Scholar
  21. 21.
    Hodng T, Human A, Goncalves O, Wong GG and Clark SC: Interleukin-6 enhances growth factor-dependent proliferation of the blast cells of acute myeloblastic leukemia. Blood 72: 823–26, 1988.Google Scholar
  22. 22.
    Füst G, Schmidt B and Vrga L: Clinical significance of hypereomplementemia. In: New aspects of complement structure and function. (Erdei A. Ed.). RG. Landes Company. Austin 1994.Google Scholar

Copyright information

© Arányi Lajos Foundation 1995

Authors and Affiliations

  • Béla Schmidt
    • 1
  • Márta Válay
    • 1
  • Sarolta Nahajevszky
    • 1
  • Ervin Pitlik
    • 1
  • György Füst
    • 1
  1. 1.Department of ImmunopathologyNational Institute of Haematology, Blood Transfusion and ImmunologyBudapestHungary

Personalised recommendations